key: cord-0725930-1q581c8x
authors: Rathe, Jennifer A; Hemann, Emily A; Eggenberger, Julie; Li, Zhaoqi; Knoll, Megan L; Stokes, Caleb; Hsiang, Tien-Ying; Netland, Jason; Takehara, Kennidy K; Pepper, Marion; Gale, Michael
title: SARS-CoV-2 Serologic Assays in Control and Unknown Populations Demonstrate the Necessity of Virus Neutralization Testing
date: 2020-12-25
journal: J Infect Dis
DOI: 10.1093/infdis/jiaa797
sha: 323eb5d10e4c3dc87087cc758d121bf9df4ef968
doc_id: 725930
cord_uid: 1q581c8x

BACKGROUND: To determine how serologic antibody testing outcome links with virus neutralization of SARS-CoV-2, we evaluated a unique set of individuals for SARS-CoV-2 antibody level and viral neutralization. METHODS: We compared serum Ig levels across platforms of viral antigens and antibodies with 15 positive and 30 negative SARS-CoV-2 controls followed by viral neutralization assessment. We then applied these platforms to a clinically relevant cohort of 114 individuals with unknown histories of SARS-CoV-2 infection. RESULTS: In controls, the best performing virus-specific antibody detection platforms were SARS-CoV-2 receptor binding domain (RBD) IgG [specificity 87%, sensitivity 100%, positive predictive value (PPV) 100%, negative predictive value (NPV) 93%], spike IgG3 [specificity 93%, sensitivity 97%, PPV 93%, NPV 97%], and nucleocapsid protein (NP) IgG [specificity 93%, sensitivity 97%, PPV 93%, NPV 97%]. Neutralization of positive and negative control sera showed 100% agreement. 20 unknown individuals had detectable SARS-CoV-2 antibodies with 16 demonstrating virus neutralization. Spike IgG3 provided the highest accuracy for predicting serologically positive individuals with virus neutralization activity [Misidentified 1/20 unknowns compared to 2/20 for RBD and NP IgG]. CONCLUSION: The coupling of virus neutralization analysis to a spike IgG3 antibody test is optimal to categorize patients for correlates of SARS-CoV-2 immune protection status.

A c c e p t e d M a n u s c r i p t Background SARS-CoV-2 has infected millions of people globally. Several serological assays to detect SARS-CoV-2 antibodies have been developed but their utility is hindered by limited sensitivity and specificity, and unclear correlation with viral neutralization [1] [2] [3] . Current interpretation of antibody test results is difficult given that individuals with virus-specific antibodies may not exhibit neutralization activity. False positives from any single assay also confound clinical interpretation serologic test results, warranting coupled analyses of virus-specific antibody titer and virus neutralization activity.

For other well-studied viral respiratory infections and associated vaccine efficacy, established threshold antibody titers correlate with protective immunity from symptomatic infection and this relationship is likely to hold true for SARS-CoV-2 [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . The majority of SARS-CoV-2 infected individuals produce neutralizing antibodies [1, 14, 15] . There have been rare cases of re-infection described despite > 9 months of SARS-CoV-2 outbreaks and spread across the world. The re-infection cases lacked assessment of SARS-CoV-2 specific immunity prior to reinfection in that antibody titers and SARS-CoV-2 specific lymphocyte responses were not measured [16] [17] [18] . While the presence of neutralizing antibodies against SARS-CoV-2 may serve as a correlate of protective immunity, the longevity and threshold titer level of protective antibodies is unknown.

The main problem facing assessment of immune correlates of protection against SARS-CoV-2 is consensus on an accurate, high throughput testing strategy.

Comparisons across antibody testing platforms reveal that no single test performs with 100% sensitivity and specificity [1, 2, [19] [20] [21] [22] . Further, no single test has consistently predicted viral neutralization with the detection of any particular anti-A c c e p t e d M a n u s c r i p t SARS-CoV-2 antibody type. These less than ideal test characteristics likely reflect a time-dependent decrease in the correlative relationship between antibody levels and the strength of viral neutralization [3, 14, 23, 24] . Antibody test platforms differ in the antibody isotypes detected (IgG, IgM, IgA, etc.); the immune system production of isotypes is time-dependent and is variably related to viral neutralization [25, 26] . An accurate and consistent SARS-CoV-2 antibody-testing platform has not been identified even when using ideal, control populations [14, 15, 27, 28] . Few studies have evaluated test performance in populations where past infection status and time from infection are unknown nor have such cohorts undergone coupled evaluation of antibody titer and viral neutralization activity [29] . Evaluation of both control and unknown populations in a comprehensive manner is needed to determine an accurate, consistent testing strategy to identify individuals with correlates of viral neutralization and protective immunity to SARS-CoV-2.

In our study we compare combinations of four viral antigens and five human antibody isotype ELISA platforms in control and unknown exposure populations coupled to classic viral neutralization studies, revealing that a specific combination approach of antibody isotype and neutralization activity of virus-specific antibody best determines exposure and possible protection to SARS-CoV-2.

Sample collection. Venipuncture collected 6-10 mls of blood in EDTA blood collection tubes and spun at 1000 rcf for 10 minutes. Plasma was separated, inactivated in a 56˚C water bath for 1 hour, and stored at -80C.

ELISA. ELISA assays were performed as previously described [28] . Briefly, highbinding plates (ThermoScientific) were coated with SARS-CoV-2 RBD [28] , SARS-CoV-2 spike [30] , or UV-inactivated SARS-CoV-2 (WA1, BEI resources) and A c c e p t e d M a n u s c r i p t incubated overnight at 4°C. Plates were blocked in PBST + 3% milk for 1hr at RT.

Three-fold serial dilutions of plasma were added to plates in biological duplicates.

Samples and the positive control spike-binding antibody CR3022 (Abcam, ab273073) were included on plates with IgG antibody binding. Following 2hr incubation and washes, anti-human secondary antibodies conjugated to HRP were diluted 1:3000 and added to plates: IgG (Thermofisher 31410), IgG1 (Southern Biotech 9054), IgG3 (Southern Biotech 9210), IgM (Sigma A6907), IgA (Sigma A0295). To recapitulate this study, we recommend use of the same secondary antibodies, given potential differences in performance of antibodies from different commercial sources. Following 1hr incubation and washes, SigmaFast OPD was added to plates. Ten minutes later, 2M H 2 SO 4 was added to wells stopping the reaction and plates read at an absorbance of 490nm (BioTek Epoch). OD values for each sample dilution were plotted and area under the curve (AUC) was calculated using Prism. AUC analyses perform more accurately to inform outcomes compared to endpoint titer; we designed our experiments to apply AUC analyses [31, 32] .

Plaque reduction neutralization test (PRNT). PRNT analyses were performed as previously described [33] . Briefly, four-fold serial dilutions of heat inactivated plasma was mixed 1:1 with 600 PFU/ml SARS-CoV-2 WA-1 (BEI resources) in DPBS Table   1 ). Analyses of the unknowns (Group A and B) with the IgM assays identified fewer positive samples compared to their IgG counterpart. However, all of the positives that were identified on the IgM assays were also identified on the IgG RBD and spike assays with one exception. All positive and negative controls as well as any unknowns identified as positive for IgG antibody titers against RBD or spike were additionally assessed for IgG1, IgG3, and IgA spike specific antibodies ( Figure 2B ). showed detectable neutralization. The 10 unknown samples near the ELISA cut-offs but designated as 'negative' were also negative for virus neutralization.

SARS-CoV-2 PRNT results provide key context to interpret ELISA results and functional evidence of viral neutralization. Table 1 illustrates the sensitivity, specificity, PPV and NPV measurements based on the positive and negative control subjects' antibody reactivity to each of the ELISA platform assays. Specificity and NPV are superior for spike IgG3 and NP IgG; therefore, these two platforms will identify fewer false positive samples compared to RBD and spike IgG. Sensitivity and PPV are best for RBD IgG, spike IgG1, and spike IgA platforms resulting in less false negative identifications. Overall, three platforms have the most desirable testing characteristics including RBD IgG, spike IgG3, and NP IgG. Figures 4A and B summarize and connect the ELISA and PRNT data. The R 2 correlation between the magnitude of specific ELISA platform antibody detection and neutralization strength is highest for RBD and spike IgG. PRNT percent agreement was calculated for each platform as the number of subjects positive by specific ELISA platforms that were also positive for neutralization for controls samples and unknowns; RBD IgG and spike IgG3 had the highest percent agreement with PRNTs across all cohorts.

Subject misidentifications are discordant results between specific ELISA platforms and neutralization not accounted for by the PRNT percent agreement calculations.

The spike IgG3 platform had the least number of misidentifications followed by NP IgG and RBD IgG. Figure 4B Sequential ELISA assay testing platforms have been proposed to increase sensitivity and specificity of SARS-CoV-2 antibody testing [28, 29] . Figure 5 compares sequential ELISA assays using sensitivity, specificity, PRNT agreement and PRNT misidentifications. No two sequential ELISA assays outperformed spike IgG3.

Using detectable neutralization to identify positive unknown samples, we antibodies at the time of this study was estimated at 3.5% with a 95% CI of 1.3 -7.3%. Comparison of exposed and unexposed cohorts shows a significant increase in the frequency of detection of neutralizing SARS-CoV-2 antibodies in those with a known exposure to infected individuals.

Our study shows that a two-tiered testing strategy of ELISA followed by PRNT of positive ELISA samples is the most accurate way to assess humoral immunity to SARS-CoV-2, and that anti-spike IgG3 is the best predictor of presence of neutralizing antibodies. We completed comprehensive analyses of multiple ELISA SARS-CoV-2 platforms coupled with the gold standard of viral neutralization testing to determine a testing strategy least likely to identify false positives and most A c c e p t e d M a n u s c r i p t predictive of SARS-CoV-2 neutralization. Relying on results from a single analysis of testing performance or testing only in control populations did not provide enough information to assess test performance. We found that having paired neutralization studies in control and unknown populations was key to interpreting results of the ELISAs for SARS-CoV-2.

Three ELISA platforms are top performers when we prioritize high specificity and NPV, high PRNT agreement, and low misidentification of subjects: RBD IgG, spike IgG3, and NP IgG. Spike IgG3 surpasses RBD IgG because of its superior specificity and therefore a lower likelihood of false positives as well as its superior prediction of neutralization in our unknown population (MI = 1/20 vs. 2/20). Of note, the R 2 for RBD IgG was higher compared to the lower correlation for spike IgG3.

However, this difference is challenging to interpret given the finding in other studies with variable and waning correlation with RBD IgG to neutralization (R 2 ranging from 0.5 -0.8) when assessed in larger positive control groups [14, 23, 24] . Our positive controls were collected around the same time from infection onset and may explain the high correlation. In assessing unknown populations with our platforms, we found that despite the higher correlation with PRNT, RBD IgG performed less well at predicting neutralization compared to spike IgG3. With the variable reported values of R 2 for RBD and spike platforms, this outcome measure does not appear to be a dependable measurement of performance for SARS-CoV-2 ELISA platforms to predict neutralization.

Across the ELISA platforms investigated, our data supports the use of spike IgG3 as the best initial screening test to predict neutralization but with the important caveat of our limited sample size. Many of the parameters of test performance were similar for RBD IgG, spike IgG3, and NP IgG. However, spike IgG3 edged out both A c c e p t e d M a n u s c r i p t NP and RBD IgG with the ability to predict neutralization (% PRNT agreement and misidentification). Expanded studies comparing these three platforms with larger sample sizes would be beneficial. RBD and NP IgG platforms already have FDA emergency approval, with the NP IgG platform having the highest specificity and most comprehensive validation [34, 35] . The NP IgG assay is likely to be limited in its ability to predict antibody neutralization activity due to internal NP localization within the intact virion being inaccessible to antibodies in vivo. This consideration is especially relevant for vaccine responses, as current vaccines being launched for human application are designed to generate immunity against the virion spike protein [35, 36] . Spike IgG3 platforms have not been developed but represent a highly promising platform given that IgG3 isotypes are thought to be more effective at viral neutralization compared to other IgG subtypes [25, 26] .

Classic PRNTs are expensive and time-consuming due to laboratory biosafety requirements. However, development of pseudovirus systems have demonstrated high correlation with the SARS-CoV-2 PRNT assay, which would allow for highthroughput sample analysis of neutralizing antibodies [14, 37, 38] . Coupling of a pseudovirus system with spike IgG3 ELISA would provide an accurate and practical two-tiered testing method to use within a standard clinical laboratory to assess for possible correlates of immunity against SARS-CoV-2.

Lastly, we estimated the prevalence of individuals with detectable SARS-CoV-2 neutralizing antibodies in the Seattle area. Our sample size is very small and therefore, unavoidably biased. The United States Center for Disease Control (CDC) reported a prevalence of 1.13% in samples obtained from the same time frame but their study suffers from sampling bias given the unknown population utilized [39] .

The CDC study prevalence estimate could be either an over or underestimate. We A c c e p t e d M a n u s c r i p t propose that the 95% CI (1.3 -7.3%) range found in this study offers a more accurate estimate of SARS-CoV-2 prevalence in our community compared to a point prevalence estimate.

In this study, we show how neutralizing assays serve as a check on the accuracy of SARS-CoV-2 antibody screening tests. Rapid, significant contributions by scientists worldwide have produced serologic SARS-CoV-2 data that has been consistent in one important way: variability. Our study confirms this high variability in serologic assay performance and provides further data that no single serologic assay provides perfect prediction for viral neutralizing ability. Two-tiered testing would allow parsing of subjects into groups important for further study in the setting of large-scale vaccine trials (1) those with positive ELISA antibody detection and confirmed neutralization and (2) those with positive ELISA antibody detection but no evidence of neutralization. Group 1 would allow tracking of subjects with known neutralization titers for evidence of reinfection vs. possible protective immunity. Group 2 would allow study for increased identification of true false positives vs. individuals that do not develop functional and/or lasting neutralizing antibodies. Therefore, a two-tiered testing strategy in which a high-throughput pseudovirus assay is coupled to an accurate serologic assay would provide key data to identify subjects with possible protective immunity to SARS-CoV-2, and to assess vaccine efficacy. At the time of this study we were unable to evaluate sera from vaccine clinical trial studies.

However, mRNA vaccines against the spike protein have demonstrated detectable antibodies with RBD and spike IgG platforms similar to the platforms investigated here [40] [41] [42] .

To our knowledge this is the first study to comprehensively assess serologic assay performance in an unknown cohort across antigen and antibody isotype A c c e p t e d M a n u s c r i p t comparisons in order to determine a practical and accurate method to determine the presence of SARS-CoV-2 neutralizing antibodies. By coupling ELISA with virus neutralization assessment, we were able to determine the accuracy of testing based on the key functional outcome of viral neutralization. Pseudoneutralization or FRNT assays provide a comparable test of neutralization to PRNTs and could be rapidly developed with a new spike IgG3 or an existing ELISA platform for two-tiered testing [14, 37, 43] . Our study provides compelling evidence that a two-tiered testing M a n u s c r i p t A c c e p t e d M a n u s c r i p t 

Brief clinical evaluation of six highthroughput SARS-CoV-2 IgG antibody assays

Clinical performance of different SARS-CoV-2 IgG antibody tests

Development and validation of IMMUNO-COV™: a highthroughput clinical assay for detecting antibodies that neutralize SARS-CoV-2

Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella

Detection of antibodies to varicella-zoster virus using a latex agglutination assay

Loss of varicella zoster virus antibodies despite detectable cell mediated immunity after vaccination

The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection

Mumps antibody levels among students before a mumps outbreak: in search of a correlate of immunity

Viremia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus

The role of seroepidemiology in the comprehensive surveillance of vaccine-preventable diseases

Measles antibody: reevaluation of protective titers

Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal

Calibration and Evaluation of Quantitative Antibody Titers for Measles Virus by Using the BioPlex 2200

Rapid generation of neutralizing antibody responses in COVID-19 patients

Antibody responses to SARS-CoV-2 in patients with COVID-19

COVID-19 re-infection by a phylogenetically distinct SARScoronavirus-2 strain confirmed by whole genome sequencing

Genomic Evidence for a Case of Reinfection with SARS-CoV-2

Predictors of severe symptomatic laboratory-confirmed SARS-COV-2 reinfection

Evaluation of the EUROIMMUN Anti-SARS-CoV-2 ELISA Assay for detection of IgA and IgG antibodies

Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies

Diagnostic performance of 7 rapid IgG/IgM antibody tests and the Euroimmun IgA/IgG ELISA in COVID-19 patients

Performance of six SARS-CoV-2 immunoassays in comparison with microneutralisation

Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents

Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications

Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases

Human immunoglobulin G and immunoglobulin G subclasses: biochemical, genetic, and clinical aspects

Antibody Detection and Dynamic Characteristics in Patients with COVID-19

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Serological identification of SARS-CoV-2 infections among children visiting a hospital during the initial Seattle outbreak

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

An ELISA assay using a combination of recombinant proteins from multiple strains of Orientia tsutsugamushi offers an accurate diagnosis for scrub typhus

Absorbance summation: A novel approach for analyzing high-throughput ELISA data in the absence of a standard

Single-dose replicating RNA vaccine induces neutralizing antibodies against SARS-CoV-2 in nonhuman primates

Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in

Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test

Coronavirus pathogenesis

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

An mRNA Vaccine against SARS-CoV-2 -Preliminary Report

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

A c c e p t e d M a n u s c r i p t